RO.CH

331

+0.49%↑

NOVN.CH

122.8

+0.92%↑

LONN.CH

513.6

+1.34%↑

SDZ.CH

63.86

+3.3%↑

STMN.CH

83.44

+1.76%↑

RO.CH

331

+0.49%↑

NOVN.CH

122.8

+0.92%↑

LONN.CH

513.6

+1.34%↑

SDZ.CH

63.86

+3.3%↑

STMN.CH

83.44

+1.76%↑

RO.CH

331

+0.49%↑

NOVN.CH

122.8

+0.92%↑

LONN.CH

513.6

+1.34%↑

SDZ.CH

63.86

+3.3%↑

STMN.CH

83.44

+1.76%↑

RO.CH

331

+0.49%↑

NOVN.CH

122.8

+0.92%↑

LONN.CH

513.6

+1.34%↑

SDZ.CH

63.86

+3.3%↑

STMN.CH

83.44

+1.76%↑

RO.CH

331

+0.49%↑

NOVN.CH

122.8

+0.92%↑

LONN.CH

513.6

+1.34%↑

SDZ.CH

63.86

+3.3%↑

STMN.CH

83.44

+1.76%↑

Search

Bachem Holding AG

Gesloten

SectorGezondheidszorg

66.95 2.53

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

65.35

Max

67.15

Belangrijke statistieken

By Trading Economics

Inkomsten

49M

99M

Verkoop

69M

382M

K/W

Sectorgemiddelde

30.96

57.05

Dividendrendement

1.46

Winstmarge

25.83

Werknemers

2,130

EBITDA

35M

107M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+31.02% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.46%

2.52%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

522M

4.6B

Vorige openingsprijs

64.42

Vorige sluitingsprijs

66.95

Nieuwssentiment

By Acuity

43%

57%

134 / 349 Rangschikking in Healthcare

Bachem Holding AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Nike, RH, NCino

31 mrt 2026, 22:35 UTC

Winsten

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisities, Fusies, Overnames

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mrt 2026, 23:50 UTC

Acquisities, Fusies, Overnames

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mrt 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mrt 2026, 23:21 UTC

Winsten

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mrt 2026, 23:14 UTC

Marktinformatie
Winsten

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mrt 2026, 23:12 UTC

Marktinformatie

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss Widens >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mrt 2026, 21:46 UTC

Acquisities, Fusies, Overnames

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mrt 2026, 21:36 UTC

Marktinformatie

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mrt 2026, 21:33 UTC

Winsten

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mrt 2026, 21:32 UTC

Winsten

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mrt 2026, 21:28 UTC

Winsten

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mrt 2026, 21:26 UTC

Winsten

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mrt 2026, 21:25 UTC

Winsten

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mrt 2026, 21:24 UTC

Marktinformatie
Winsten

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mrt 2026, 21:22 UTC

Winsten

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mrt 2026, 21:22 UTC

Winsten

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mrt 2026, 21:21 UTC

Winsten

Nike's Digital Channel Still Too Promotional, CFO Says

31 mrt 2026, 21:20 UTC

Winsten

Nike CEO: Converse Remains Important to Portfolio

Peer Vergelijking

Prijswijziging

Bachem Holding AG Prognose

Koersdoel

By TipRanks

31.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 83.2 CHF  31.02%

Hoogste 110 CHF

Laagste 60 CHF

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bachem Holding AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Sentiment

By Acuity

134 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.
help-icon Live chat